Retatrutide Before and After: Clinical Trial Weight Loss Data
When people search for "retatrutide before and after," they want to see real results. We get it. Before-and-after stories are powerful because they make abstract clinical data feel personal and concrete. But we are going to do something different here. Instead of sharing unverifiable anecdotes or cherry-picked success stories, we are going to walk you through the actual clinical trial data that shows what happened to real patients, documented under rigorous scientific conditions.
The truth is, the clinical data for retatrutide is more impressive than any individual before-and-after story could be. We are talking about average weight loss numbers that exceed anything previously seen with a medication. We are talking about liver fat reductions of 86%. We are talking about waist circumference changes, BMI shifts, and body composition improvements that were measured with medical imaging, not bathroom scales.
This is what "before and after" actually looks like when you have the full picture.
Phase 2 Trial Results: 48 Weeks of Data
The phase 2 trial of retatrutide was published in the New England Journal of Medicine in June 2023. It enrolled 338 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. Participants were randomized to receive either placebo or one of several retatrutide doses: 0.5 mg, 4 mg, 8 mg, or 12 mg weekly.
The trial lasted 48 weeks, and the results were striking from every angle.
Weight Loss at 24 Weeks
At the 24-week mark, roughly six months of treatment, the results were already impressive:
| Group | Weight Loss at 24 Weeks |
|---|---|
| Placebo | -2.1% |
| Retatrutide 0.5 mg | -7.2% |
| Retatrutide 4 mg | -12.9% |
| Retatrutide 8 mg | -17.1% |
| Retatrutide 12 mg | -17.5% |
At 24 weeks, the 8 mg and 12 mg groups were showing similar results, which makes sense because the 12 mg group was still in its titration phase at this point and had only recently reached full maintenance dosing. The full separation between dose groups became more apparent over the following months.
For perspective, semaglutide 2.4 mg (Wegovy) produced approximately 12% weight loss at 24 weeks in its STEP 1 trial. The retatrutide 8 mg and 12 mg groups were already exceeding that at the halfway point.
Weight Loss at 48 Weeks
The 48-week results are where retatrutide separated itself from every other medication in the obesity treatment space:
| Group | Weight Loss at 48 Weeks | Approximate Pounds Lost (for 250 lb starting weight) |
|---|---|---|
| Placebo | -2.1% | ~5 lbs |
| Retatrutide 0.5 mg | -8.7% | ~22 lbs |
| Retatrutide 4 mg | -17.5% | ~44 lbs |
| Retatrutide 8 mg | -22.8% | ~57 lbs |
| Retatrutide 12 mg | -24.2% | ~61 lbs |
The 12 mg group lost nearly a quarter of their body weight in less than a year. And the weight loss curves were still trending downward at week 48, meaning these patients had not yet reached their maximum weight loss. Longer treatment would likely have produced even greater reductions.
What 24% Weight Loss Actually Looks Like
Numbers on a page can be hard to visualize, so let us put 24% weight loss in concrete terms for different starting weights:
| Starting Weight | 24% Weight Loss | Ending Weight |
|---|---|---|
| 200 lbs | 48 lbs | 152 lbs |
| 225 lbs | 54 lbs | 171 lbs |
| 250 lbs | 60 lbs | 190 lbs |
| 275 lbs | 66 lbs | 209 lbs |
| 300 lbs | 72 lbs | 228 lbs |
| 350 lbs | 84 lbs | 266 lbs |
For someone starting at 275 pounds, we are talking about losing 66 pounds. That is the kind of transformation that changes clothing sizes by 4-6 sizes, eliminates the need for seatbelt extenders on airplanes, and resolves conditions like sleep apnea and knee pain. It is life-changing weight loss by any measure.
Phase 3 TRIUMPH-4 Results: 68 Weeks
The TRIUMPH-4 trial extended the observation period to 68 weeks (approximately 16 months) and enrolled a larger patient population. This trial compared the 4 mg and 12 mg maintenance doses against placebo, giving us our best look yet at what retatrutide can do with longer treatment.
Headline Numbers
The TRIUMPH-4 results, presented at major medical conferences and in peer-reviewed publications, showed:
- 12 mg group: 28.7% average body weight loss at 68 weeks
- 4 mg group: Approximately 17-18% average body weight loss at 68 weeks
- Placebo: Approximately 3% weight loss at 68 weeks
The 28.7% number deserves emphasis. No anti-obesity medication has ever produced this level of weight loss in a phase 3 trial. To put it in context:
- Semaglutide 2.4 mg (Wegovy) produced ~15% at 68 weeks in STEP 1
- Tirzepatide 15 mg (Zepbound) produced ~22.5% at 72 weeks in SURMOUNT-1
- Retatrutide 12 mg produced ~28.7% at 68 weeks in TRIUMPH-4
Retatrutide at 12 mg exceeded tirzepatide's best result by more than 6 percentage points, and tirzepatide was already considered a generational leap beyond semaglutide.
Average Pounds Lost
The average participant in the TRIUMPH-4 12 mg group lost approximately 71.2 pounds. That is not a hypothetical number or a projection. That is the measured average across the study population. Some participants lost considerably more, and some lost less, but the group average was over 70 pounds of weight loss.
For context, the average starting weight of participants in the trial was approximately 248 pounds, with an average BMI around 37-38. These were people with clinically significant obesity, not people looking to lose a few vanity pounds. The weight loss they achieved brought many of them into the overweight or even normal weight BMI category.
Responder Analysis: How Many People Lost Significant Weight?
Average numbers can be misleading if a few extreme responders skew the results. But the responder analysis from TRIUMPH-4 shows that the results were broadly distributed:
- Percentage losing 5% or more of body weight: Over 95% of the 12 mg group
- Percentage losing 10% or more: Over 90% of the 12 mg group
- Percentage losing 15% or more: Over 80% of the 12 mg group
- Percentage losing 20% or more: Over 70% of the 12 mg group
- Percentage losing 25% or more: Over 50% of the 12 mg group
More than half of the patients on the highest dose lost over a quarter of their body weight. And over 90% hit the 10% threshold that is considered clinically meaningful for resolving obesity-related comorbidities. This is not a medication that works brilliantly for a few and fails for the rest. The response was remarkably consistent.
Body Composition Changes: Beyond the Scale
Weight loss alone does not tell the full story. What matters is what kind of weight you are losing. Losing muscle is bad. Losing fat, especially visceral fat, is what actually improves health. The retatrutide trials measured body composition using advanced imaging techniques, and the results were encouraging.
Fat Mass vs. Lean Mass
In the phase 2 trial, body composition analysis showed that the majority of weight lost was fat mass. Across the dose groups, approximately 70-75% of total weight lost was fat tissue, with the remaining 25-30% being lean mass (which includes muscle, water, and other non-fat tissue).
This ratio is actually very typical for weight loss of this magnitude, whether achieved through medication, surgery, or diet. When you lose large amounts of weight, some lean mass loss is inevitable because the body requires less structural muscle to carry a lighter frame. The key question is whether the lean mass loss is excessive, and with retatrutide, it does not appear to be.
For comparison, bariatric surgery typically results in 20-35% of weight loss coming from lean mass, a similar ratio to what was seen with retatrutide. And studies of semaglutide and tirzepatide have shown similar patterns.
Visceral Fat Reduction
Visceral fat, the fat stored deep in the abdomen around your organs, is the most metabolically dangerous type of fat. It drives insulin resistance, inflammation, and cardiovascular risk in ways that subcutaneous fat (the fat under your skin) does not.
Retatrutide produced substantial reductions in visceral fat. While the exact imaging data varies by study, the dramatic reductions in waist circumference (discussed below) and the metabolic improvements strongly suggest significant visceral fat loss. The glucagon receptor component of retatrutide may specifically target liver and visceral fat, which would explain some of the metabolic benefits seen beyond what weight loss alone would predict.
Liver Fat Reduction: The 86% Number
One of the most striking findings from the retatrutide trials came from the liver fat substudy. This was a subset of phase 2 participants who underwent MRI-based measurement of liver fat content before and after treatment.
What the Data Showed
At the 12 mg dose, retatrutide reduced liver fat content by an average of 86% at 48 weeks. To understand why this matters, some background helps.
Non-alcoholic fatty liver disease (NAFLD), now more commonly called metabolic dysfunction-associated steatotic liver disease (MASLD), affects roughly 30-40% of adults in the United States. In people with obesity, the prevalence is even higher, estimated at 70-80%. MASLD is the accumulation of excess fat in the liver, and if left untreated, it can progress to inflammation (steatohepatitis), fibrosis, cirrhosis, and eventually liver failure or liver cancer.
There are currently very few effective treatments for MASLD. Weight loss of 5-10% can reduce liver fat, and bariatric surgery has shown benefit, but no medication specifically approved for MASLD has been widely available until very recently.
The Retatrutide Liver Fat Results in Detail
- Patients starting with significant liver fat (above 10% liver fat fraction, indicating established MASLD) saw the most dramatic improvements
- At the 12 mg dose, average liver fat decreased from approximately 16-17% to approximately 2-3%
- A liver fat fraction below 5% is considered normal, meaning most patients on the 12 mg dose achieved complete resolution of their fatty liver
- The 4 mg dose also produced significant liver fat reduction, though less dramatic than 12 mg
- The glucagon receptor activity of retatrutide is believed to drive much of this liver fat benefit, as glucagon directly stimulates hepatic fat oxidation (fat burning in the liver)
This 86% reduction is substantially greater than what has been seen with semaglutide (approximately 50% liver fat reduction) or tirzepatide (approximately 50-55% reduction). The triple agonist mechanism, specifically the glucagon component, appears to give retatrutide a meaningful advantage for liver health.
Why This Matters for Patients
If you have been told you have a "fatty liver," this data is significant. An 86% average reduction means that most patients on the highest dose of retatrutide went from having clinically significant fatty liver to having essentially normal liver fat levels. That is a transformation from a disease state to a healthy state, something that is very difficult to achieve with lifestyle changes alone.
Waist Circumference Changes
Waist circumference is one of the best clinical indicators of visceral fat and overall cardiometabolic risk. A waist circumference above 40 inches in men or 35 inches in women is associated with significantly elevated risk of heart disease, type 2 diabetes, and metabolic syndrome.
Phase 2 Results
In the phase 2 trial, waist circumference reductions were substantial and dose-dependent:
| Dose Group | Average Waist Circumference Reduction |
|---|---|
| Placebo | -1.8 cm (~0.7 inches) |
| 0.5 mg | -6.4 cm (~2.5 inches) |
| 4 mg | -12.5 cm (~4.9 inches) |
| 8 mg | -16.2 cm (~6.4 inches) |
| 12 mg | -18.3 cm (~7.2 inches) |
The 12 mg group lost over 7 inches from their waist circumference on average. That is a dramatic physical transformation. For someone who started with a 48-inch waist, ending at just under 41 inches represents a visible, measurable change that affects everything from clothing fit to physical comfort to cardiovascular risk.
TRIUMPH-4 Results
The longer TRIUMPH-4 trial showed even greater waist circumference reductions, consistent with the greater overall weight loss at 68 weeks. The 12 mg group saw waist circumference reductions approaching 20 cm (nearly 8 inches) on average.
BMI Changes
BMI (Body Mass Index) is an imperfect but widely used measure of weight relative to height. The clinical trials documented substantial BMI shifts across all dose groups.
BMI Category Shifts
Many participants moved down one or even two BMI categories during the trial:
- Patients who started in the Class III obesity range (BMI 40+) often moved to Class I obesity or even overweight
- Patients who started in the Class I or II obesity range (BMI 30-40) frequently moved to the overweight category (BMI 25-30)
- Some patients who started in the lower obesity range moved into the normal weight category (BMI under 25)
In the 12 mg group, the average BMI reduction was approximately 10-11 BMI points at 68 weeks. For a patient who started at BMI 38, that would bring them down to approximately BMI 27-28, which crosses the threshold from obesity into the overweight category. That transition is clinically meaningful because it is associated with substantial reductions in health risks.
Real-World BMI Context
To illustrate what these BMI changes look like practically:
| Height | Starting Weight (BMI ~38) | Weight After 28.7% Loss | New BMI |
|---|---|---|---|
| 5'4" | 221 lbs | 158 lbs | ~27 |
| 5'7" | 243 lbs | 173 lbs | ~27 |
| 5'10" | 265 lbs | 189 lbs | ~27 |
| 6'0" | 280 lbs | 200 lbs | ~27 |
| 6'2" | 296 lbs | 211 lbs | ~27 |
The consistency of ending BMI across different heights is because the percentage weight loss applies proportionally. A 28.7% loss brings someone from a BMI of 38 to approximately 27, regardless of their height.
Factors That Affect Individual Results
While the average numbers from clinical trials are impressive, individual results will always vary. Understanding what factors influence outcomes helps set realistic expectations.
Starting Weight and BMI
In the clinical trials, patients with higher starting BMI tended to lose more weight in absolute terms (more pounds) but similar or slightly lower weight in percentage terms compared to patients with lower starting BMI. This means a patient starting at 350 lbs might lose more total pounds than a patient starting at 200 lbs, but the percentage of body weight lost could be similar or slightly less.
The phase 2 data showed that percentage weight loss was fairly consistent across BMI subgroups, which is encouraging. It suggests that retatrutide is effective across the full spectrum of obesity severity.
Sex
Women and men in the retatrutide trials showed broadly similar percentage weight loss. Some earlier GLP-1 trials had shown slightly different response patterns by sex, but the retatrutide data did not reveal a clinically meaningful sex-based difference in efficacy. Both men and women can expect similar percentage reductions at a given dose.
Age
The clinical trials enrolled adults across a range of ages, typically 18-75 years. Age-stratified analyses have not shown a major impact on efficacy, though older adults may be more susceptible to lean mass loss during rapid weight loss and may benefit from concurrent resistance exercise and adequate protein intake.
Diabetes Status
Patients with type 2 diabetes have historically shown slightly less weight loss with GLP-1 medications compared to patients without diabetes. This pattern held true in the retatrutide trials as well, with patients with type 2 diabetes losing somewhat less weight than those without. However, the retatrutide results in the diabetes population were still very strong, and these patients also gained the additional benefit of significant A1C reduction and improved glycemic control.
Prior Weight Loss Medication Use
Some trial participants had previously used other weight loss medications. The data suggests that prior medication use did not significantly impact retatrutide's effectiveness. Patients who had previously taken semaglutide or tirzepatide could still achieve significant additional weight loss with retatrutide, likely due to the additional glucagon receptor activity.
Diet and Exercise
All participants in the clinical trials received standard lifestyle counseling, which included guidance on reduced-calorie diet (typically a 500 calorie per day deficit) and increased physical activity (usually 150 minutes per week of moderate activity). The trials did not test retatrutide without any lifestyle component, so the results represent medication plus basic lifestyle modifications.
Patients who were more adherent to diet and exercise recommendations likely saw better results, though individual adherence data is not publicly available from the trials. It is reasonable to expect that combining retatrutide with a consistent diet and exercise program will produce results at the upper end of the clinical trial range.
Genetics
Obesity has a significant genetic component, and genetic variation likely influences how individuals respond to retatrutide. Some patients may be more or less responsive to GLP-1, GIP, or glucagon receptor activation based on their genetic profile. This area of pharmacogenomics is still in its early stages, and we do not yet have specific genetic markers that predict retatrutide response.
Realistic Expectations by Starting Weight
Based on the clinical trial data, here are realistic weight loss expectations for the 12 mg dose at 68 weeks (approximately 16 months of treatment). These are averages. Individual results will fall above and below these numbers.
| Starting Weight | Expected Loss (28.7% average) | Expected Final Weight | Likely Range (10th-90th percentile) |
|---|---|---|---|
| 180 lbs | ~52 lbs | ~128 lbs | 130-165 lbs |
| 200 lbs | ~57 lbs | ~143 lbs | 145-180 lbs |
| 225 lbs | ~65 lbs | ~160 lbs | 160-200 lbs |
| 250 lbs | ~72 lbs | ~178 lbs | 175-220 lbs |
| 275 lbs | ~79 lbs | ~196 lbs | 190-240 lbs |
| 300 lbs | ~86 lbs | ~214 lbs | 210-265 lbs |
| 350 lbs | ~100 lbs | ~250 lbs | 245-310 lbs |
A few important notes on these projections. First, the "likely range" column is estimated based on the distribution of results in the trials. Individual results can fall outside this range. Second, patients at the lower end of starting weights may not have been well-represented in the trials (most participants had BMI of 30+), so the projections for a 180 lb starting weight should be taken with extra caution. Third, these are 68-week results; longer treatment may produce additional weight loss.
Weight Loss Timeline: What to Expect Month by Month
One of the most common questions is about the timeline of weight loss. How quickly will results appear? Based on the trial data, here is an approximate month-by-month picture for the 12 mg dose group:
Month 1 (Weeks 1-4, Dose: 0.5 mg)
Weight loss is minimal, typically 1-2% of body weight. This translates to roughly 2-5 pounds for most patients. You may notice slightly decreased appetite, but the dose is sub-therapeutic. This is the adaptation phase.
Month 2 (Weeks 5-8, Dose: 1 mg)
Weight loss begins to accelerate. Cumulative loss is typically around 3-5%. Appetite suppression becomes more noticeable. You may start to feel the medication working.
Month 3 (Weeks 9-12, Dose: 2 mg)
Weight loss continues to pick up. Cumulative loss is around 6-9%. At this point, the changes may become visible to people around you. Clothing may feel noticeably looser.
Months 4-5 (Weeks 13-20, Dose: 4-8 mg)
This is the acceleration phase. Weight loss is rapid, sometimes 1-2 pounds per week. Cumulative loss reaches approximately 12-17%. Physical changes are now obvious. Many patients report dramatic improvements in energy, mobility, and mood during this period.
Months 6-8 (Weeks 21-32, Dose: 12 mg maintenance)
Full maintenance dose is reached. Weight loss continues at a steady pace. Cumulative loss reaches approximately 18-23%. Side effects have typically stabilized. Patients often describe feeling like a different person at this stage.
Months 9-16 (Weeks 33-68, Dose: 12 mg maintenance)
Weight loss continues but at a gradually slowing rate as the body approaches a new equilibrium. The final average of 28.7% is reached around week 68. Many patients are still losing weight at this point, just more slowly.
Cardiovascular and Metabolic Markers: The Numbers Behind the Numbers
Weight loss is the headline, but the metabolic improvements may be even more important for long-term health. Here is what the clinical data showed beyond the scale:
Blood Pressure
Retatrutide produced significant reductions in systolic blood pressure across all dose groups. The 12 mg group saw average reductions of approximately 8-12 mmHg in systolic blood pressure. For patients with borderline or Stage 1 hypertension, this reduction could be enough to move them into the normal range without additional blood pressure medication.
A1C (In Patients with Type 2 Diabetes)
In the diabetes population, retatrutide produced dramatic A1C reductions. The 12 mg dose reduced A1C by approximately 2.0 percentage points on average. Many patients achieved A1C levels below 5.7%, which is technically below the threshold for prediabetes. This level of glycemic improvement is comparable to what is seen with bariatric surgery.
Lipid Profile
- Triglycerides: Reduced by approximately 25-35% at the 12 mg dose
- LDL cholesterol: Modest reductions observed across dose groups
- HDL cholesterol: Moderate improvements, particularly at higher doses
Inflammatory Markers
C-reactive protein (CRP), a marker of systemic inflammation, decreased significantly with retatrutide treatment. This is consistent with the reduction in visceral fat, which is a major source of pro-inflammatory signaling. Reduced inflammation has wide-ranging health benefits, from cardiovascular protection to improved joint health to potentially reduced cancer risk.
Comparing Retatrutide Results to Other Treatments
To put retatrutide's before-and-after data in perspective, here is how it compares to other weight loss interventions:
| Treatment | Typical Weight Loss | Timeline |
|---|---|---|
| Diet and exercise alone | 3-5% | 6-12 months |
| Orlistat (Xenical/Alli) | 5-7% | 12 months |
| Naltrexone/bupropion (Contrave) | 5-8% | 12 months |
| Semaglutide 2.4 mg (Wegovy) | 15-17% | 68 weeks |
| Tirzepatide 15 mg (Zepbound) | 20-22.5% | 72 weeks |
| Retatrutide 12 mg | 28.7% | 68 weeks |
| Gastric sleeve surgery | 25-30% | 12-18 months |
| Gastric bypass surgery (Roux-en-Y) | 30-35% | 12-18 months |
Retatrutide is the first medication to produce weight loss results that are comparable to bariatric surgery. The 12 mg dose achieved results in the same range as gastric sleeve surgery and approaching the results of gastric bypass, but without any surgical procedure, general anesthesia, hospitalization, or permanent anatomical changes.
What the Data Does Not Show
It is important to be transparent about what the clinical trial data cannot tell us:
- Long-term maintenance: We do not yet know what happens beyond 68 weeks. Will the weight stay off with continued treatment? Will some regain occur? These are critical questions that longer studies will need to answer.
- Weight regain after stopping: Based on data from semaglutide and tirzepatide, significant weight regain is likely if the medication is discontinued. It is reasonable to expect the same pattern with retatrutide, but this has not been specifically studied.
- Real-world results: Clinical trial participants are carefully selected, monitored, and supported. Real-world results may differ. Adherence tends to be lower outside of trials, and some patients may not tolerate the full titration schedule.
- Individual variation: The numbers in this article are averages. Some patients lost considerably more than the average, and some lost considerably less. You cannot guarantee that any specific individual will match the average trial result.
- Cosmetic outcomes: Clinical trials measured weight, BMI, waist circumference, and body composition. They did not systematically document cosmetic outcomes like loose skin, changes in facial appearance, or body shape changes. These are legitimate concerns for patients losing large amounts of weight.
Setting Your Own Expectations
If you are considering retatrutide when it becomes available, here is how to think about what "before and after" might look like for you:
Conservative estimate: Assume you will achieve 60-70% of the trial average. This accounts for the fact that real-world adherence is typically lower than clinical trial adherence, and you may not reach or tolerate the highest dose. At 60% of the 12 mg result, you would be looking at roughly 17% weight loss, which is still excellent.
Moderate estimate: Assume you will match the trial average. This is reasonable if you are adherent with your medication, follow dietary and exercise guidance, and tolerate the full dose well. That would mean approximately 25-29% weight loss depending on your dose.
Optimistic estimate: Some patients will exceed the average. If you combine retatrutide with consistent exercise, a high-protein diet, and careful attention to lifestyle factors, you may land in the upper end of the distribution.
The most important thing is to work with your physician to set goals that are specific to your health situation. The "right" amount of weight loss is the amount that resolves or significantly improves your weight-related health conditions and improves your quality of life. For some people, that might be 15%. For others, it might be 30% or more.
The Bottom Line
The clinical trial data for retatrutide represents a genuine breakthrough in obesity treatment. Average weight loss of 28.7% at the highest dose, with liver fat reductions of 86%, waist circumference reductions of nearly 8 inches, and metabolic improvements across the board, these are the kinds of results that change the trajectory of a person's health.
We have presented this data as honestly as we can. These are averages from carefully controlled trials, not guarantees of individual results. But the consistency of the data across trials, dose groups, and patient populations gives us strong confidence that retatrutide will be a transformative treatment for obesity when it becomes available.
If you are interested in exploring your options for medical weight management right now, there are effective FDA-approved treatments available today. A physician who specializes in obesity medicine can help you understand your options and create a plan that is right for your specific situation.